TREACE JOHN R 4

4 · TREACE MEDICAL CONCEPTS, INC. · Filed Apr 29, 2021

Form 4

Period: 2021-04-27

Director

Transactions

Conversion
Common Stock
2021-04-27+427,875→ 2,707,856 total(indirect: John R. Treace and Ginger D. Treace JTTEN)
Sale
Common Stock
2021-04-27$17.00/sh−401,250$6,821,250→ 2,306,606 total(indirect: John R. Treace and Ginger D. Treace JTTEN)
Other
Series A Preferred Stock
2021-04-27+9,906→ 9,906 total(indirect: John R. Treace and Ginger D. Treace JTTEN)
→ Common Stock (9,906 underlying)
Conversion
Series A Preferred Stock
2021-04-27−427,875→ 0 total(indirect: John R. Treace and Ginger D. Treace JTTEN)
→ Common Stock (427,875 underlying)

Holdings

Footnotes (4)

[F1]Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.
[F2]These shares were sold by the Reporting Person as a selling stockholder in conjuction with the Issuer's Form S-1 filing, Registration Number 333-254863. The offering closed on April 27, 2021. The reported sale price reflects the price at which the Reporting Person sold shares to the underwriters.
[F3]The Reporting Person disclaims beneficial ownership of shares held in trusts for which he is a co-trustee.
[F4]The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend.

Documents

1 file